BBK Worldwide^® Blog

Getting Decentralized Right

What Matters to Patients

We know the industry is ready to embrace decentralized clinical trials. But what about patients? What do they think about decentralized clinical trials? What elements are important to them? And what should sponsors consider when designing such trials?

To dig deep, we spoke one-on-one with Phil Kelly, a bladder cancer patient and advocate. He shares his experience and insight in Part 1 of this two-part series on the patient perspective.

One-on-One with BBK Worldwide® Director of
Tech Experience Dena Raffa 

There's no question that digital technology is changing the way we engage with patients and altering expectations for the patient experience. As part of our Pharma15 Live! series, we sat down with BBK's Director of Tech Experience Dena Raffa to get her perspective on current trends.

Raffa has been instrumental in many of BBK's software solutions and digital technologies, and most recently she has led the development of BBK's new patient engagement portal - a first of its kind for clinical trial participants.

PHARMA15 LIVE!

Coordination to Creation: Initiating a New Study Partnership

We often hear about unburdening patients and site staff during clinical trial participation – but what about unburdening sponsors during the clinical trial lifecycle? As BBK Worldwide® Creative Director for Strategic Services, I assist in prescribing the programs and services that best align with the protocol to support a study’s participants on an individual basis. From there, my team and I work closely with our account executives to seamlessly bring our full-service study support from proposal to coordination to creation.

Improving Diversity and Inclusion in Clinical Trials

One-on-One with Advarra

Get an IRB's perspective on improving diversity and inclusion in clinical trials by watching our interview with Michele Russell-Einhorn, Chief Compliance Officer and Institutional Official at Advarra.

PHARMA15 LIVE!

How Do Patients Feel About Hybrid
and Decentralized Clinical Trials?

What Are Must-Haves for
a Positive Patient Experience?

Patient advocates take center stage in this Pharma15 Live! overtime segment and share their thoughts on hybrid and decentralized clinical trials.

Moderated by BBK Worldwide^® Founding Principal Bonnie A. Brescia, this segment continues the conversation from a Patients as Partners Europe panel and answers questions asked by study sponsors in attendance.

What do doctors and nurses think about solutions designed to make clinical trials easier to conduct? Are they helpful? Do they alleviate burdens? And which ones do they prefer?

In this special Pharma15 Live! segment, BBK Worldwide^® industry experts Matt Kibby and Aaron Fleishman discuss recent Study Voices survey results that shed light on this topic. They examine doctor and nurse perspectives on services designed to provide support in conducting clinical trials — including services for virtual, hybrid, and decentralized clinical trials.

“We were looking at whether or not doctors and nurses at sites that were conducting clinical trials would appreciate different types of services that assist with their ability to conduct them."

-Matt Kibby, Principal, President, BBK Worldwide

The Road to Reopening

In our newest Pharma15 Live! episode, Principal of RSG Services Rob Laurens provides guidance on managing clinical trial patient travel as COVID-19 restrictions ease and countries and study sites start to reopen.

Rob answers common questions and highlights the advantages of thoughtful pre-planning and contingency preparation. Watch now and discover strategies clinical trial sponsors can leverage to maximize patient safety and engagement during COVID-19 and beyond.

Download the eBook

Because there's a lot to consider in terms of managing patient travel as COVID-19 restrictions ease, we've captured guidance in a special eBook to download and review at your convenience.

As the director and one of the producers of Pharma15 Live! I wanted to share with you some insights into what we’ve learned through an amazing three seasons! First of all, if you were to tell me at the beginning of our series that it would even last three seasons, I’d tell you I’d be shocked – but nonetheless here we are and it’s been great!

As the country goes through the phases of reopening, what does that mean for the patient and site experience in clinical trials? PharmaTalkRadio’s Valerie Bowling discusses the future of clinical trials with Ray Dorsey, MD, Matt Kibby, and Craig Lipset in this feature podcast.

More of Your Questions Answered

In this special video clip, industry innovators Aaron Fleishman and Craig Lipset answer some of the overflow questions from our Virtual Town Hall on maintaining clinical trial momentum during COVID-19 and beyond.

This 20-minute segment features answers to your questions relating to:

• Implementation of decentralized trials
• Impact of COVID-19 on enrollment of healthy volunteers
• Biggest concerns for clinicians around remote contact with patients
• Advancing decentralized trials while not leaving behind people without access to reliable internet, electronic devices, or digital savvy
• Validating new digital endpoints for decentralized trials
• Impact of telemedicine and other decentralized trial approaches on  monitoring and source data verification (SDV)